CSPC Pharmaceutical Group Limited (CSPCY)
USD 3.05
(-2.71%)
USD 3.05
(-2.71%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 22.17 Billion CNY | -0.36% |
| 2022 | 22.25 Billion CNY | 5.31% |
| 2021 | 21.13 Billion CNY | 13.11% |
| 2020 | 18.68 Billion CNY | 17.44% |
| 2019 | 15.91 Billion CNY | 30.22% |
| 2018 | 12.21 Billion HKD | 56.46% |
| 2017 | 7.8 Billion HKD | 38.25% |
| 2016 | 5.64 Billion HKD | 29.21% |
| 2015 | 4.37 Billion HKD | 30.57% |
| 2014 | 3.34 Billion HKD | 36.77% |
| 2013 | 2.44 Billion HKD | 68.42% |
| 2012 | 1.45 Billion HKD | 21.23% |
| 2011 | 1.19 Billion HKD | -38.12% |
| 2010 | 1.93 Billion HKD | -2.94% |
| 2009 | 1.99 Billion HKD | -0.62% |
| 2008 | 2 Billion HKD | 39.56% |
| 2007 | 1.43 Billion HKD | 134.04% |
| 2006 | 614.98 Million HKD | -14.82% |
| 2005 | 721.95 Million HKD | 7.42% |
| 2004 | 672.1 Million HKD | -31.85% |
| 2003 | 986.21 Million HKD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 6.49 Billion CNY | 20.63% |
| 2024 Q2 | 5.15 Billion CNY | 0.0% |
| 2023 Q4 | 5.38 Billion CNY | -3.06% |
| 2023 Q2 | 5.71 Billion CNY | 3.63% |
| 2023 Q1 | 5.51 Billion CNY | 6.66% |
| 2023 FY | 22.17 Billion CNY | -0.36% |
| 2023 Q3 | 5.55 Billion CNY | -2.88% |
| 2022 Q3 | 5.74 Billion CNY | 3.91% |
| 2022 FY | 22.25 Billion CNY | 5.31% |
| 2022 Q1 | 5.81 Billion CNY | -13.56% |
| 2022 Q2 | 5.52 Billion CNY | -4.88% |
| 2022 Q4 | 5.17 Billion CNY | -9.92% |
| 2021 Q4 | 6.72 Billion CNY | 8.54% |
| 2021 FY | 21.13 Billion CNY | 13.11% |
| 2021 Q3 | 6.19 Billion CNY | -3.55% |
| 2021 Q1 | 6.15 Billion CNY | 22.45% |
| 2021 Q2 | 6.42 Billion CNY | 4.41% |
| 2020 Q1 | 4.95 Billion CNY | 10.11% |
| 2020 Q4 | 5.02 Billion CNY | -12.31% |
| 2020 FY | 18.68 Billion CNY | 17.44% |
| 2020 Q3 | 5.72 Billion CNY | 6.39% |
| 2020 Q2 | 5.38 Billion CNY | 8.59% |
| 2019 Q1 | 4.49 Billion CNY | 24.58% |
| 2019 Q3 | 4.46 Billion CNY | -1.07% |
| 2019 Q4 | 4.5 Billion CNY | 0.75% |
| 2019 FY | 15.91 Billion CNY | 30.22% |
| 2019 Q2 | 4.51 Billion CNY | 0.55% |
| 2018 Q1 | 3.51 Billion CNY | 25.9% |
| 2018 Q2 | 3.29 Billion CNY | -6.2% |
| 2018 Q3 | 3.38 Billion CNY | 2.72% |
| 2018 Q4 | 3.6 Billion CNY | 6.4% |
| 2018 FY | 12.21 Billion HKD | 56.46% |
| 2017 FY | 7.8 Billion HKD | 38.25% |
| 2017 Q4 | 2.79 Billion CNY | 15.13% |
| 2017 Q3 | 2.42 Billion CNY | 13.09% |
| 2017 Q2 | 2.14 Billion CNY | 8.45% |
| 2017 Q1 | 1.97 Billion CNY | 18.63% |
| 2016 Q3 | 1.6 Billion CNY | 1.8% |
| 2016 Q4 | 1.66 Billion CNY | 3.95% |
| 2016 Q2 | 1.57 Billion CNY | 7.99% |
| 2016 FY | 5.64 Billion HKD | 29.21% |
| 2016 Q1 | 1.45 Billion CNY | 7.01% |
| 2015 Q4 | 1.36 Billion CNY | 6.56% |
| 2015 FY | 4.37 Billion HKD | 30.57% |
| 2015 Q3 | 1.28 Billion CNY | -4.45% |
| 2015 Q2 | 1.33 Billion CNY | 8.29% |
| 2015 Q1 | 1.23 Billion CNY | 11.26% |
| 2014 Q4 | 1.11 Billion CNY | 5.44% |
| 2014 FY | 3.34 Billion HKD | 36.77% |
| 2014 Q1 | 973.58 Million CNY | 14.16% |
| 2014 Q2 | 1.04 Billion CNY | 7.59% |
| 2014 Q3 | 1.05 Billion CNY | 0.67% |
| 2013 Q4 | 852.79 Million CNY | 15.45% |
| 2013 FY | 2.44 Billion HKD | 68.42% |
| 2013 Q3 | 738.66 Million CNY | 0.75% |
| 2013 Q2 | 733.16 Million CNY | -9.31% |
| 2013 Q1 | 808.44 Million CNY | 0.0% |
| 2012 FY | 1.45 Billion HKD | 21.23% |
| 2011 FY | 1.19 Billion HKD | -38.12% |
| 2010 FY | 1.93 Billion HKD | -2.94% |
| 2009 FY | 1.99 Billion HKD | -0.62% |
| 2008 FY | 2 Billion HKD | 39.56% |
| 2007 FY | 1.43 Billion HKD | 134.04% |
| 2006 FY | 614.98 Million HKD | -14.82% |
| 2005 FY | 721.95 Million HKD | 7.42% |
| 2004 FY | 672.1 Million HKD | -31.85% |
| 2003 FY | 986.21 Million HKD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 36.078% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 35.369% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 26.417% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -197254.151% |
| Novartis AG | 34.18 Billion USD | 35.133% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -2882.85% |